An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

Robin, Alan L., M.D.

Status and phase: Completed; Phase 4

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: travoprost, latanoprost, or bimatoprost; Drug: Additional ocular hypotensive medication

Study type: Interventional

Identifiers

NCT00329095

GMED-01

Details and patient eligibility

About

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Full description

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently using one or two topical ocular hypotensive medications

Exclusion criteria

• Hypersensitivity to any component of medication

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)